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An experimental model of Guillain-Barré Syndrome has been established in 
recent years. Rabbits develop disease upon immunization with a single dose of 
an emulsion containing bovine brain gangliosides, KLH and complete Freund’s 
adjuvant. Within a period of four to ten weeks after immunization, they began to 
produce anti-ganglioside IgG-antibodies first, and to show clinical signs of 
neuropathy afterwards. In addition to gangliosides, KLH is a requirement for 
antibody production and disease triggering. Although KLH is commonly used as 
an immunological carrier protein, an anti-KLH-specific immune response was 
necessary for induction of both events. KLH is a glycoprotein carrying most of 
the immunogenicity in its glycan moiety. Between 20% to 80% of anti-
ganglioside IgG-antibodies present in sick rabbit sera cross-reacted with KLH, 
indicating that both immune responses are related. The terminal Gal-ß(1,3)-
GalNAc glycan (present in gangliosides and KLH) is proposed as “key” 
antigenic determinant involved in inducing the anti-ganglioside immune 
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Guillain-Barré syndrome (GBS) is an autoimmune neuropathy with a high 
mortality rate [1]. Gangliosides (self glycan-carrying molecules enriched in 
neural tissues) have been proposed as the main antigenic targets for antibodies 
mediating this disabling process [1-3]. Although intravenous immunoglobulin 
and plasma exchange have been successful therapeutic tools, current research 
is focused on the immune mechanisms involved in triggering the disease, 
aiming for an early immune intervention. Since Nagai et al. [4] described that 
ganglioside immunization induce a motor neuropathy (so called “ganglioside 
syndrome”), several laboratories have searched for an animal model of the 
disease with controversial results. Rabbits inoculated with GM1 in Freund's 
adjuvant produced anti-GM1 antibodies, but showed only minor 
electrophysiological and pathological changes [5] with no clinical symptoms [6]. 
In 2001, Yuki´s laboratory [7] described an experimental model of GBS by 
immunizing rabbits with bovine brain gangliosides (BBG). Yuki´s immunization 
protocol was slightly different than those previously used by other laboratories. 
Unlike earlier protocols using bovine serum albumin (BSA), it included keyhole 
limpet hemocyanin (KLH) as carrier protein in the immunogen. Although our 
laboratory also failed to produce the “ganglioside syndrome” in a 2002 
experiment [6], we were able to reproduce Yuki´s model of GBS more recently 
using KLH [8]. Herein we characterize the critical role played by KLH in antibody 

















2. Materials and methods 
 
2.1. Gangliosides 
Gangliosides GM1, GD1a, GD1b, and GT1b were prepared from human 
brain and used as antigens. Folch upper phase of lipid extract [9] was purified by 
reversed phase chromatography [10] and DEAE-Sephadex column 
chromatography [11]. Mono-, di-, and tri-sialoganglioside fractions were obtained 
by sequential elution from the column, using 10, 25, and 40 mM sodium acetate in 
methanol, respectively. GM1, GD1a, GD1b, and GT1b were purified from their 
proper fractions by HPLC, using an Iatrobead 8010 silica column and mixtures of 
isopropanol/hexane/water as running solvent [12]. Asialo-GM1 (GA1) was 
prepared by acid hydrolysis of bovine brain gangliosides [13], and further purified 
by DEAE-Sephadex and HPLC. Total ganglioside fraction of bovine brain (BBG) 
was prepared by Folch extraction, DEAE-Sephadex, alkaline methanolysis, and 
reversed phase chromatography. This preparation of BBG was composed by 4 
major gangliosides: GM1 (30 %), GD1a (48 %), GD1b (10 %) and GT1b (12 %). 
The preparation did not contain GA1. 
 
2.2. Immunization of rabbits 
Five hundred microliters PBS containing 2.5 mg BBG and 1 mg KLH 
(Calbiochem, San Diego, CA) or methylated BSA (Sigma, St. Louis, MO, USA) 
were emulsified in 500 l complete Freund's adjuvant (CFA). Emulsification was 
accomplished by repetitive passing mixture throw a needle (0.5 x 40 mm) using a 
disposable syringe. New Zealand male white rabbits weighting 2.5 -3 kg were 















immunized with the same inoculum without BSA, KLH or ganglioside, under the 
same protocol. Rabbits were weighed and revised weekly to detect appearance of 
clinical signs. Blood samples were taken by ear vein puncture; sera were 
separated from blood clots and frozen at -70°C until use. Several experiments 
with a total of 27 rabbits were performed, all in accordance with international and 
institutional guidelines for animal care.  
 
2.3. Enzyme-linked immunosorbent assay (ELISA) 
Fifty picomoles GM1 in 50 l methanol were pipetted into microtiter plate 
wells, and dried overnight at 37°C. Alternatively, 50 l of a solution of KLH 
(2g/ml) in sodium carbonate buffer, 0.1 M, pH: 8.3 were incubated at 4°C 
overnight and washed. Each well was blocked with 1% BSA (Sigma, St. Louis, 
MO, USA) in phosphate buffered saline (BSA-PBS) for 1 h, added with 50 l BSA-
PBS-diluted serum (starting with 1/50 dilution), incubated for 4 h, and washed with 
PBS. Binding was detected following 2 h incubation with BSA-PBS diluted 
(1/2000) peroxidase-conjugated goat anti-rabbit IgG (-chain specific; Accurate 
Chemical & Scientific Corporation, NY, USA). All incubation steps were performed 
at 4°C. After washing, color was developed in a substrate solution containing 15 
mM o-phenylenediamine and 0.015% H2O2 in 0.1 M sodium acetate buffer, pH 
5.0, at room temperature. The reaction was stopped after 30 min by addition of 
100 l 0.5 N H2SO4, and OD was measured at 450 nm. Non-specific antibody 
binding (OD value from a well not containing GM1) was subtracted from each 
measured value. All samples were analyzed in duplicates. Titer values were 
calculated as the reciprocal of the serum dilution needed to obtain half-maximal 















peroxidase-conjugated PNA (20 g/ml) for 2 h at 4ºC, followed by washing and 
color reaction development as above. 
 
2.4. Mild periodation treatment. 
Microtiter plates adsorbed with KLH were incubated (1 h, 4ºC, dark) with 50 
l of 15 mM sodium periodate in sodium acetate buffer, pH: 4.5. After washing, 
wells were treated with 50 mM sodium borohydrate in PBS for 30 min. Antibody 
and lectin binding were assayed as above. 
 
2.5. TLC-immunostaining 
A ganglioside mixture containing GA1, GM1, GD1a, GD1b, and GT1b was 
separated on TLC plates in the running solvent chloroform/ methanol/ aqueous 
0.2% CaCl2 (45:45:10) using a tank designed to obtain highly reproducible 
chromatograms [15]. After air drying, plates were coated by dipping for 90 
seconds in a 0.5% solution of poly(isobutyl) methacrylate (Aldrich Chemical Co., 
Milwaukee, WI, USA) in n-hexane-chloroform (9:1), and air-dried for 10 min. The 
plates were blocked with BSA-PBS containing 0.05 % Tween 20 (BSA-PBSt) for 1 
h, incubated overnight in BSA-PBSt diluted serum (1/1000), washed 3x with PBSt, 
incubated 2 h with peroxidase-conjugated goat anti-rabbit IgG diluted (1/5000) in 
BSA-PBSt, and tested for binding. All incubation steps were performed at 4°C. 
After washing, color was developed in a substrate solution containing 2.8 mM 4-
chloro-1-naphthol and 0.01% H2O2 in methanol/ 20 mM Tris-HCl buffer, pH 7.4 
(1:29) at room temperature. For quantitative studies, spots were measured by 
densitometry scanning at 590 λ. Usually, one plate was stained with orcinol 















Inhibition of antibody binding to plate bound ganglioside antigen was 
accomplished by incubating sera with KLH (100 µg/ml) or GA1 (0.1 mM) for 60 

















After receiving a single dose of immunogen containing BBG and KLH in 
complete Freund’s adjuvant, rabbits begun to produce anti-ganglioside IgG-
antibodies, followed by clinical signs of neuropathy one or two weeks later (see 
supplementary material). Although this association of facts is observed in all the 
immunized rabbits, their time course was different among them. Figure 1 shows 
two cases where different time lags between immunization and 
antibody/disease presence were clearly observed. Anti-ganglioside IgG-
antibodies started to be detected four or more weeks after immunization. In 
contrast, high titers of IgG-antibodies recognizing KLH were already found at 
week 2 (results not shown). Although these results indicate that different 
mechanisms could be involved in the induction of both types of antibodies, KLH 
was necessary to induce anti-ganglioside IgG-antibodies and disease (Table I, 
groups 1-3). Even more, both components had to be present together in the 
immunogen because they were ineffective if injected separately (Table I, group 
4). Replacing KLH by BSA (a classical protein used as immunological carrier) 
produced a weaker response of anti-ganglioside IgG-antibodies, and no disease 
was observed (Table I, group 5). These conditions could be reverted if KLH was 
injected in a separate site (Table I, group 6), raising antibody titers and inducing 
clinical signs. These results indicate not only that KLH functions as 
immunological protein carrier, but also that an immune response against KLH is 
a requirement for an immune response to gangliosides high enough to induce 
disease. 
Previous reports described that immunization with BBG/KLH induces 















antibodies recognize gangliosides GA1,GM1and GD1b [16] (Figure 2B). These 
structurally related gangliosides share the terminal Gal-ß(1,3)-GalNAc 
disaccharide (Figure 2A). Normal rabbit serum had low levels of anti-
ganglioside IgM-antibodies recognizing this terminal [6] (Figure 2Bb, 2Ca, 2Da). 
This antibody activity was raised by immunization with BBG alone (Figure 2Cb) 
and, unexpectedly, also in some of the rabbits immunized with KLH (Figure 
2Db). No anti-ganglioside IgG-antibody activity was detected, neither in 
preimmune (normal) sera (Figure 2Bd, 2Cc, 2Dc) nor in BBG immunized rabbits 
(Figure2Cd). In contrast, KLH-immunized rabbits showed anti-GA1 IgG-
antibodies (Figure 2Be). Although this reactivity was very low and sometimes 
transient, it was clearly detected at 1/20 serum dilutions. Most of normal anti-
ganglioside antibody binding reactivity was inhibited by preincubation with GA1, 
indicating recognition of shared epitopes (Figure 3A). The intensity of the 
immunospots was variable among different rabbits and, interestingly, a negative 
correlation between intensity of GA1 spot and time of disease onset was found 
(Figure 3B).  
The protein KLH is highly immunogenic, and very high titers of IgG-
antibodies were produced few weeks after immunizations (Figure 4A). KLH is 
glycosylated [17] and its antigenic reactivity was highly reduced by mild 
periodation (Figure 4A), a treatment that destroys some terminal sugars like 
galactose. Peanut agglutinin (PNA) is a lectin that recognizes glycans carrying 
the terminal Gal-ß(1,3)-GalNAc disaccharide, including GA1 and GM1 
gangliosides [18, 19]. PNA also bound KLH (Figure 4B), indicating that KLH 
contained the terminal disaccharide. As expected, PNA binding was completely 















These results indicated that the immune responses to KLH and to 
gangliosides could be related and, consequently, a potential cross-reactivity 
between both antibody activities was studied. For this, sera from sick rabbits 
were preincubated with soluble KLH before assaying for anti-ganglioside 
antibodies. As it is shown in Figure 5A, KLH partially inhibited antibody binding 
to gangliosides. Interestingly, a higher inhibition was obtained at the beginning 















4. Discussion  
Gangliosides are ubiquitous molecules present in most of the vertebrate 
cells and are considered self antigens. The immune response to gangliosides is 
restricted by self-tolerance,and high affinity monoclonal antibodies can only be 
elicited in ganglioside-lacking mice [20]. Rabbit serum containing anti-
ganglioside antibodies has been produced as a research tool in several 
laboratories where ganglioside function is studied [21-23], and it is widely 
known that gangliosides should be mixed with a carrier protein to get antibodies 
of the IgG isotype. BSA is frequently used as immunological carrier, leading to 
weak anti-ganglioside IgG antibody responses in rabbits that remain healthy [6] 
(Table I). The induction of clinical signs of neuropathy by immunization with 
gangliosides required the presence of KLH in the inoculum. Although this 
mollusk protein is classically used as immunological carrier protein [24], it 
cannot be replaced by BSA in order to induce the disease. In addition to its 
“carrier” function, it appears that KLH is required as immunogen in order to 
trigger the clinical signs (Table I, group 6).  
All the rabbits immunized with BBG and KLH develop the disease, but 
with differences in the time lags between immunization and emergence of 
clinical signs. Independently of the lags, anti-ganglioside IgG-antibodies were 
detected one to two weeks before the signs. These facts indicate that the 
differences in the lags between immunization and disease onset could be a 
consequence of differences in the lags of antibody induction. KLH is highly 
immunogenic, and high titers of antibodies are already induced two weeks after 
immunization. In contrast, most of the rabbits develop an immune response to 















mechanisms in the immune response to KLH and gangliosides, KLH 
immunogenicity is necessary to induce an anti-ganglioside IgG-antibody 
response high enough to trigger disease.  
KLH is a glycoprotein that contains 4 % of carbohydrates [24, 25] and 
this glycan moiety is the main component of its antigenicity [26] (Figure 4A). 
One of the glycan structures present in KLH is the so-called “PNA determinant” 
(terminal Gal-ß(1,3)-GalNAc). This structure is included in the core structure of 
gangliosides, and is found as a terminal disaccharide in GA1, GM1 and GD1b 
gangliosides (Figure 2A). We previously described that antibodies induced by 
immunization with BBG together with a carrier protein recognize these three 
gangliosides [6, 16]. Fine specificity studies indicated these antibodies are 
composed by different populations recognizing epitopes formed by terminal Gal-
ß(1,3)-GalNAc, with a major or minor contribution of NeuNAc [6, 16]. On the 
other hand, most of anti-ganglioside IgM-antibodies from normal rabbit 
recognize epitopes involving terminal Gal-ß(1,3)-GalNAc without participation of 
NeuNAc. These facts indicated both types of antibodies are related, and that 
immune antibodies could originate from normal antibodies. In this context, the 
repertoire of antibodies induced by immunization with KLH could include 
antibodies recognizing epitopes related to terminal Gal-ß(1,3)-GalNAc. 
Populations of lymphocytes producing these particular anti-KLH antibodies can 
be positively selected by immunogenically active gangliosides, thus raising anti-
ganglioside antibody levels. At the beginning of the immune response, these 
anti-ganglioside antibodies will cross-react with KLH. It is expected that later, 
when more specific anti-ganglioside antibodies are selected, this cross-















these particular anti-KLH antibodies originating disease-associated anti-
ganglioside antibodies are related to the GA1 structure. This is supported by 
two results: i. Anti-GA1-specific IgG-antibodies (not cross-reacting with 
GM1/GD1b) were produced in KLH immunized rabbits. ii. Disease triggering 
was faster in those rabbits containing higher reactivity of normal anti-GA1 IgM-
antibodies. However, lymphocytes with this specificity could not be stimulated 
by GM1/GD1b. Consequently, they should change their specificity in order to be 
recognized by these gangliosides. We called “binding site drift” to this process 
of fine specificity modification in the lymphocytes, and it was proposed to 
explain the origin of anti-ganglioside antibodies in neuropathies [20, 27, 28]. 
After “drifting”, these new lymphocytes can undergo binding site refinement and 
affinity maturation, similar to their conventional counterpart. The process would 
occur at random (drift), a fact that can explain the differences in the 
immunization/disease lags observed in the sick rabbits (Figure 1). 
 
Conclusion: We can summarize our interpretation of results as follows: during 
immunization with KLH, lymphocytes that produce antibodies recognizing a 
GA1-like structure are stimulated. Some of these lymphocytes mutate their 
surface immunoglobulin binding site, modifying their fine specificity and starting 
to recognize GM1/GD1b (“drift”). These “drifted” lymphocytes can now be 
stimulated by immunogenically active GM1/GD1b gangliosides present in the 
immunogen, triggering the immune response. On the contrary, in the absence 
of KLH and its associated immune response only lymphocytes producing 
normally occurring low affinity anti-GM1/GD1b IgM-antibodies can be 
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Table I: Immunogen requirements of disease induction.  
 Immunogen Anti-GM1 IgG-
antibodies 
Clinical 
signs Group Site 1 Site 2 
1 BBG/KLH - + + 
2 BBG - - - 
3 KLH - - - 
4 KLH BBG - - 
5 BBG/BSA - +/- - 
6 BBG/BSA KLH + + 
 
Rabbits were immunized with an emulsion containing CFA and the stated 
compounds. Clinical signs included tremor, limb weakness and paralysis. Anti-
GM1 antibodies were measured by ELISA: (+) antibody titers between 5700 


















Legends to the figures 
 
Figure 1: Time course of disease induction. Rabbits immunized with an 
emulsion containing BBG, KLH and CFA were weekly weighed and revised to 
detect appearance of clinical signs. Sera (1/1000 dilutions) were tested for anti-
ganglioside IgG-antibodies by TLC-immunostaining (inserts).  Arrows indicate the 
apparition of clinical signs. Results obtained with two rabbits (A and B) with 
different time lags between immunization and disease triggering is shown. 
 
Figure 2: Anti-ganglioside antibodies characterization. A: Ganglioside structure 
recognized by rabbit serum antibodies. Representative rabbit sera from groups 
1 (B), group 2 (C) and group 3 (D) were analyzed for anti-ganglioside IgM or 
IgG-antibodies by TLC-immunostaining. Sera were used at 1/20 dilutions, 
except for IgG determination from group 1 rabbit where serum was used at 
1/1000 dilutions. A TLC plate was stained with orcinol reagent for chemical 
detection of gangliosides. 
 
Figure 3: Normally occurring anti-ganglioside IgM-antibodies in rabbits. Rabbit 
preimmune sera (1/20 dilution) were assayed for anti-ganglioside IgM-
antibodies by TLC immunostaining. Sera were preincubated with and without 
soluble GA1 (0.1 mM). Results with two representative sera are shown (A). 
Seven preimmune sera from sick rabbits (Table I, group 1) were analyzed by 
TLC immunostaining, and spot intensity was quantified by colorimetric 















Figure 4: KLH glycan characterization. KLH was adsorbed on ELISA plates and 
subjected to mild periodation. Treated (●) and non-treated (○) plates were 
assayed for A: Anti-KLH IgG-antibodies present in a group 3 rabbit serum. B: 
PNA lectin binding. 
 
Figure 5: Cross-reactivity between anti-ganglioside and anti-KLH antibodies. A: 
One thousand dilutions of sera from group 1 rabbits werepreincubated with or 
without soluble KLH (100 g/ml). After 1 h at RT, sera were used for TLC-
immunostaining (A). Antibody binding was quantified by densitometric scanning 
of immunospots. Percentages of inhibition obtained in serial serum samples 
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 Rabbits immunized with gangliosides and KLH develop an experimental 
neuropathy. 
 Anti-ganglioside IgG-antibodies are induced shortly before disease 
triggering. 
 The protein KLH is required both as immunological carrier and as 
specific immunogen. 
 Part of induced anti-ganglioside IgG-reactivity cross-reacts with KLH. 
 Disease triggering time lags correlate with preimmune anti-GA1 IgM-
antibody levels. 
 The terminal glycan Gal-ß(1,3)-GalNAc is proposed as “key” antigenic 
determinant. 
